BLU.TO - BELLUS Health Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.56
+0.01 (+1.82%)
At close: 3:50PM EDT
Stock chart is not supported by your current browser
Previous Close0.55
Open0.56
Bid0.54 x 0
Ask0.57 x 0
Day's Range0.55 - 0.57
52 Week Range0.33 - 0.62
Volume334,853
Avg. Volume95,955
Market Cap66.919M
Beta0.98
PE Ratio (TTM)N/A
EPS (TTM)-0.06
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • CNW Group18 hours ago

    BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937

    LAVAL, QC, July 19, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that the Japan Patent Office has issued a decision to grant Japanese Patent No. 2015-555508, which grants claims covering the composition of matter of BELLUS Health's lead drug candidate, BLU-5937, and related imidazopyridine compounds, in addition to pharmaceutical compositions comprising BLU-5937 and uses thereof. With the grant of this new Japanese patent, BLU-5937 has now obtained patent protection with claims covering its composition of matter in all major pharmaceutical markets, including the U.S., Europe, Japan and China.

  • ACCESSWIRE11 days ago

    Toronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / July 9, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange shaved off 1.81 points, or 0.24%, to finish at 740.10. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).

  • ACCESSWIRE11 days ago

    Today's Research Reports on Acerus Pharmaceuticals, IMV, Valeant Pharmaceuticals and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / July 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • CNW Group11 days ago

    BELLUS Health Initiates Phase 1 Clinical Study for its Chronic Cough Drug Candidate, BLU-5937

    LAVAL, QC, July 9, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced the initiation of healthy subjects dosing in a Phase 1 clinical study for BLU-5937, its lead drug candidate for the treatment of chronic cough. Preclinical studies demonstrated that BLU-5937 is a highly selective P2X3 antagonist exhibiting a potent anti-tussive effect without affecting taste perception, with an excellent safety profile. The main objectives of the Phase 1 clinical study are to assess the safety, tolerability (including taste perception) and pharmacokinetic profile of BLU-5937 in healthy subjects.

  • CNW Group23 days ago

    BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium

    LAVAL, QC, June 27, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today presented preclinical data on its lead drug candidate, BLU-5937 for the treatment of chronic cough. Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, provided a review of the data at the 2018 International Cough Symposium in London, UK. In summary, animal studies demonstrated that BLU-5937 is a highly selective P2X3 antagonist exhibiting a potent anti-tussive effect without affecting taste perception.

  • Baystreetlast month

    Stocks in play: BELLUS Health Inc.

    Announced that Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, will present ...

  • CNW Grouplast month

    BELLUS Health to Present at the 2018 International Cough Symposium

    LAVAL, QC, June 20, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, will present the Company's lead drug candidate for the treatment of chronic cough, BLU-5937, at the 2018 International Cough Symposium in London, UK, on Wednesday June 27, 2018 at 4:30 pm BST (11:30 am EDT). A copy of the presentation will be available on the Company's website at www.bellushealth.com following the event.

  • ACCESSWIRElast month

    Today's Research Reports on Aptose Biosciences, Fennec Pharmaceuticals, Valeant Pharmaceuticals and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • ACCESSWIRElast month

    Today's Free Reports BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / June 7, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange gained 7.25 points, or 0.94%, to finish at 775.10. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).

  • CNW Group2 months ago

    BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2018

    - Completed studies required to submit clinical trial application for BLU-5937 for chronic cough - - Announces voting results from Annual Meeting - LAVAL, QC , May 15, 2018 /CNW/ - BELLUS Health Inc. (TSX: ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Oncolytics Biotech, CardioComm Solutions, BELLUS Health and Aphria

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • ACCESSWIRE3 months ago

    Canadian Exchanges Stock Scanner BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / May 04, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange shaved off 0.86 points, or 0.11%, to finish at 771.25. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).

  • CNW Group3 months ago

    BELLUS Health Responds to Recent Share Price Appreciation and Increased Trading Activity

    LAVAL, QC, April 30, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today responded to a request from the Investment Industry Regulatory Organization of Canada (IIROC) to comment on recent trading activity of BELLUS Health's shares. BELLUS Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes the Company's lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs.

  • CNW Group3 months ago

    BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference

    LAVAL, QC, April 26, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including an update on its lead program, BLU-5937 for the treatment of chronic cough, on Thursday May 3, 2018 at 9:30 am ET at the 2018 Bloom Burton & Co. Healthcare Investor Conference. The Bloom Burton & Co. Healthcare Investor Conference will be held at the Sheraton Centre Toronto Hotel on May 2 and 3, 2018. BELLUS Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Acerus Pharmaceuticals, TSO3, BELLUS Health and ImmunoVaccine

    NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE4 months ago

    Canadian Exchanges Stock Scanner BELLUS Health, Helius Medical Technologies, Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / April 4, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, ...

  • ACCESSWIRE5 months ago

    Toronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / March 5, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, ...

  • CNW Group5 months ago

    BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017

    LAVAL, QC, Feb. 21, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the year ended December 31, 2017.

  • ACCESSWIRE6 months ago

    Canadian Exchanges Stock Scanner, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / January 24, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical ...

  • Baystreet6 months ago

    Stocks in play: BELLUS Health Inc.

    Announced that it has received from Taro Pharmaceuticals Inc. a milestone payment of $400,000 in relation ...

  • CNW Group6 months ago

    BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals

    LAVAL, QC, Jan. 9, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that it has received from Taro Pharmaceuticals Inc. ("Taro") a milestone payment of $400,000 in relation to the sale of its wholly-owned subsidiary Thallion Pharmaceuticals Inc. ("Thallion") in March 2017. On March 16, 2017, BELLUS Health entered into a share purchase agreement with Taro for the sale of Thallion, including all the rights to the drug candidate Shigamab™. As consideration, BELLUS Health received a cash payment of $2.3 million on closing and was entitled to receive a payment of $0.4 million upon the completion of a pre-established milestone event.

  • CNW Group6 months ago

    BELLUS Health to Present at Biotech Showcase™ 2018 Conference

    LAVAL, QC, Jan. 4, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will provide a corporate overview of the Company, including BLU-5937, its lead program for chronic cough, at the upcoming Biotech Showcase™ 2018 Conference on Tuesday, January 9 at 9:30 am PT (12:30 pm ET) in San Francisco, CA, at the Hilton San Francisco Union Square. BELLUS Health's presentation will also be available on the Company's website at www.bellushealth.com following the event. Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.

  • ACCESSWIRE7 months ago

    Research Reports on BELLUS Health Helius Medical Technologies, Resverlogix, and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical ...

  • CNW Group7 months ago

    BELLUS Health Closes $20M Common Share Financing

    LAVAL, QC, Dec. 12, 2017 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today closed its previously announced equity offering, issuing a total of 52,631,580 common shares for gross proceeds of $20 million (the "Offering"). The majority of the Offering was subscribed to by healthcare specialized institutional investors and also included the participation by members of the senior management team and board of directors of the Company. This, in addition to the participation of members of the Company's leadership team, is a testament to the potential of BLU-5937 as a best-in-class treatment for chronic cough," said Roberto Bellini, President and CEO of BELLUS Health.

  • PR Newswire7 months ago

    IIROC Trade Resumption - BLU

    TORONTO , Dec. 5, 2017 /CNW/ - Trading resumes in: Company: BELLUS Health Inc. TSX Symbol: BLU (all issues) Resumption (ET): 9:45 AM IIROC can make a decision to impose a temporary suspension (halt) of ...